Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company has shown steady growth in its vaping segment, while the future of Heat-Not-Burn (HNB) products looks promising, although increased expenditure is impacting short-term profitability [1][2] - The company is expected to face challenges with disposable products due to tightening regulations in various countries, but there is potential for growth in the APV and HNB segments [2][3] - The U.S. market is crucial for the company, with expectations for the launch of new HNB products, which could enhance market share and revenue [3] Financial Performance Summary - In Q1 2025, the company reported a net profit of 192 million yuan, a decrease of 43.4% year-on-year, with total comprehensive income of 208 million yuan, down 32.9% year-on-year [1] - Revenue for 2024 is projected at 11.799 billion yuan, with a growth rate of 6%, and net profit expected to be 1.303 billion yuan, reflecting a decline of 21% year-on-year [5][6] - The company’s adjusted net profit forecasts for 2025, 2026, and 2027 are 1.411 billion yuan, 2.337 billion yuan, and 3.032 billion yuan, respectively, with corresponding P/E ratios of 39.9X, 24.1X, and 18.6X [4][5] Market and Product Insights - The company is positioned as a key supplier for British American Tobacco, which is expanding its HNB product offerings in various markets, including the U.S. [3] - The anticipated launch of the IQOS ILUMA in the U.S. is expected to further pressure traditional cigarette sales, leading to increased focus on HNB product development [3] - The company is expected to benefit from its unique production capabilities and technology, which may help mitigate tariff pressures in the U.S. market [4]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company is experiencing steady growth in its vaping segment, while the future of Heat-Not-Burn (HNB) products looks promising, although increased expenses are impacting short-term profitability [1] - The company reported a net profit of 192 million yuan for Q1 2025, a decrease of 43.4% year-on-year, with total comprehensive income of 208 million yuan, down 32.9% year-on-year [1] - The report anticipates a stable revenue stream for Q1, with profit pressure primarily due to increased expenses and a higher tax rate compared to the previous year [1] Summary by Sections Market Environment - The report highlights regulatory changes affecting disposable vaping products in Belgium, France, and the UK, which are expected to pressure the company's performance in this segment [2] - The company is expected to see a recovery in its APV and refillable products overseas, with a trend of year-on-year improvement anticipated [2] HNB Product Development - The company is positioned to benefit from the expansion of HNB products in the US market, with expectations for the launch of new products by PMI [3] - The report notes that the US market is crucial for the company, with projected revenue and adjusted operating profit contributions of 44% and 54%, respectively [3] Financial Projections - The company is projected to achieve adjusted net profits of 1.41 billion yuan in 2025, 2.34 billion yuan in 2026, and 3.03 billion yuan in 2027, with corresponding P/E ratios of 39.9X, 24.1X, and 18.6X [4] - Total revenue is expected to grow from 11.8 billion yuan in 2024 to 17.1 billion yuan in 2027, with a compound annual growth rate of approximately 23% [5] - The report outlines a decrease in net profit for 2024, followed by a recovery in subsequent years, with growth rates of 8% in 2025 and 66% in 2026 [5][7] Key Financial Metrics - The company’s total assets are projected to increase from 27.65 billion yuan in 2024 to 35.85 billion yuan in 2027, indicating a strong growth trajectory [6][7] - The report provides detailed financial metrics, including operating income, net profit, and earnings per share (EPS), with EPS expected to rise from 0.21 yuan in 2024 to 0.49 yuan in 2027 [5][6]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company achieved a profit of 1.47 billion yuan in 2024, representing a year-on-year growth of 254%, with a dividend payout ratio of 73% [1] - Revenue for 2024 reached 8.5 billion yuan, an increase of 167.5% year-on-year, aligning with the upper end of the profit forecast [1] - The company's same-store sales growth exceeded 120%, ranking first in revenue and sales efficiency among jewelry brands in mainland China [2] - The gross margin remained stable at 41.2%, while the net profit margin increased significantly to 17.3% [3] - The company is expanding its brand influence and optimizing its product offerings, with plans to open 7 new stores and upgrade 4 existing ones in 2024 [4] Financial Summary - The company forecasts revenues of 17.85 billion yuan in 2025, 24.92 billion yuan in 2026, and 31.12 billion yuan in 2027, with respective year-on-year growth rates of 110%, 40%, and 25% [5] - The projected net profit for 2025 is 3.58 billion yuan, with a year-on-year growth of 143% [5] - The earnings per share (EPS) are expected to be 9.47 yuan in 2024, increasing to 38.63 yuan by 2027 [6]

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The company's revenue for 2024 is projected to be 8.624 billion HKD, representing a year-on-year increase of 17.05%. However, the net profit attributable to shareholders is expected to decline by 31.2% to 342 million HKD due to increased dividend withholding tax and fair value changes [8][20] - The increase in uranium prices has significantly boosted the company's pre-tax performance, but the net profit has decreased due to new tax regulations in Kazakhstan and losses from the exchange of shares with Paladin [8][20] - The average sales price of uranium is 75.04 USD/lb U3O8, while the average production cost has risen to 80.80 USD/lb U3O8, reflecting a 4 USD increase year-on-year [12][13] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 86.24 billion HKD, with a pre-tax profit of 8.14 billion HKD, marking a 48.3% increase year-on-year. However, the net profit attributable to shareholders fell to 342 million HKD, a decrease of 31.2% [8][20] - The company's uranium trading revenue was 86.24 billion HKD, with a segment loss of 0.95 billion HKD. Investment income from other segments was 10.16 billion HKD, with significant contributions from Fission Uranium and Paladin [8][20] Production and Costs - The company self-traded 1,294 tons of uranium in 2024, maintaining production levels from the previous year. The production cost increased to an average of 80.80 USD/lb U3O8 due to rising raw material prices and increased underground resource usage tax [12][13] - The average production cost across mines rose to 24 USD/lb U3O8, primarily due to a supply shortage of sulfuric acid and increased taxes linked to higher sales prices [12][13] Market Trends - The spot price of natural uranium peaked above 100 USD/lb U3O8 at the beginning of 2024 but subsequently declined, with a 27.7% decrease in trading volume year-on-year. Long-term contract prices, however, showed a stable upward trend, rising from 58 USD/lb U3O8 to 80 USD/lb U3O8 [14][20] - The report anticipates a downward adjustment in profit forecasts due to declining spot prices and increased resource usage tax rates, projecting net profits of 635 million HKD, 785 million HKD, and 836 million HKD for 2025-2027 [20]

证券研究报告·公司点评报告·软件服务(HS) 九方智投控股（09636.HK） 收购 Yintech Financial+核心信息系统，进军 海外金融 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,965 | 2,306 | 3,579 | 4,139 | 4,692 | | 同比（%） | 6.23% | 17.33% | 55.22% | 15.64% | 13.36% | | 归母净利润（百万元） | 191 | 272 | 1,293 | 1,701 | 2,245 | | 同比（%） | -58.59% | 42.81% | 374.64% | 31.55% | 32.00% | | EPS-最新摊薄（元/股） | 0.46 | 0.66 | 3.13 | 4.12 | 5.44 | | P/E（现价&最新摊薄） | 62.83 | 44.00 | 9.27 | 7.05 | 5.34 | [Ta ...

融创服务 01516.HK 公司研究 | 动态跟踪 | | 物管业务稳健增长，关联方影响进一步消 | | --- | --- | | 化 | | 核心观点 公司发布 2024 年度业绩公告，营业收入约为 69.7 亿元，同比基本持平；归母净亏损约 4.51 亿元，同比增亏 3.7%；归母核心净利润约 8.0 亿元，同比基本持平。 盈利预测与投资建议 ⚫ 维持增持评级，调整目标价至 1.73 港元。根据公司 24 年业绩公告，我们调整了对公 司在管面积和各项业务收入及毛利率预测值，下调了费用率的预测，同时考虑到 24 年公司进一步计提应收款减值，调整后公司 24-26 年 EPS 预测值为-0.15/0.16/0.16 元（原预测 24-25 年为 0.24/0.26 元），可比公司 25 年 PE 为 10x，对应目标价 1.73 港元（1 港元=0.926 人民币）。 风险提示 ⚫ 关联方应收账款压力进一步增大。外拓具备不确定性。资产减值损失风险。 公司主要财务信息 | | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | - ...

医疗美容 可复美延续高增长，可丽金提速，胶原龙头潜力可期 巨子生物（02367.HK） 证券研究报告/公司研究简报 2025 年 04 月 07 日 | 评级： | 买入（首次） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | | 2024A | 2025E | 2026E | 2027E | | 分析师：郑澄怀 | | 营业收入（百万元） | | 3,526 | 5,539 | 7,056 | 8,893 | 11,021 | | | | 增长率 yoy% | | 48% | 57% | 27% | 26% | 24% | | 执业证书编号：S0740524040004 | | 归母净利润（百万元） | | 1,452 | 2,062 | 2,532 | 3,102 | 3,819 | | Email：zhengch@zts.com.cn | | 增长率 yoy% | | 109% | 42% | 23% | 23% | 23% | | | | 每股收益（ ...

研究报告 Research Report 康哲药业 China Medical System Holdings (867 HK) 2024 年业绩释放压力，创新转型持续推进 Pressure from 2024 performance release, innovation and transformation continue to advance [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$8.28 目标价 HK$9.96 HTI ESG 2.0-2.5-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$20.20bn / US$2.60bn 日交易额 (3 个月均值) US$7.02mn 发行股票数目 2,440mn 自由流通股 (%) 49% 1 年股价最高最低值 HK$10.02-HK$6.24 注：现价 HK$8.28 为 2025 年 04 月 0 ...

研究报告 Research Report 7 Apr 2025 亚盛医药 Ascentage Pharma (6855 HK) 国内商业化表现稳健，全球化创新进入加速期 Domestic commercialization remains solid, while global innovation enters an accelerated phase [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$45.40 目标价 HK$51.90 HTI ESG 5.0-4.4-5.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$15.81bn / US$2.03bn 日交易额 (3 个月均值) US$18.75mn 发行股票数目 348.27mn 自由流通股 (%) 70% 1 年股价最高最低值 HK$47.70-HK$15.70 注：现价 HK$44.85 为 2025 ...

证券研究报告 | 2025年04月07日 绿城中国（03900.HK） 优于大市 业绩承压，销售拿地优于行业平均 归母净利润-49%。2024 年公司实现营业收入 1585 亿元，同比增长 20.7%； 归母净利润 16 亿元，同比下降 49%。公司归母净利润下降的主要原因是计提 资产减值及公允价值减少共 49 亿元。 销售拿地优于行业平均。2024 年公司实现总销售面积 1409 平方米，同比下 降 9%；实现总销售金额 2768 亿元，同比下降 8%，显著优于行业平均水平， 位居行业前三。其中自投销售 1718 亿元，归属公司权益金额为 1206 亿元。 公司聚焦高能级城市，一、二线销售额占比高达 79%，首开去化率为 82%， 回款率达 104%，继续维持高位。分区域看，公司长三角、环渤海区域分别占 销售总额的 70%、13%。 2024 年公司新增项目 42 个，新增建面 418 万平方米，对应新增货值 1088 亿 元，同比下降 24%，但仍优于行业平均水平。公司新增土储中，北上杭占比 51%，一二线城市占比 92%，布局得到优化。截至 2024 年末，公司土储总货 值 4496 亿元，总建筑面积 ...